Welcome to our dedicated page for Centessa Pharmaceuticals Plc news (Ticker: CNTA), a resource for investors and traders seeking the latest updates and insights on Centessa Pharmaceuticals Plc stock.
Centessa Pharmaceuticals plc (Nasdaq: CNTA) is a clinical-stage pharmaceutical company centered on developing orexin receptor 2 (OX2R) agonist therapies for sleep–wake and neuroscience-related disorders. The CNTA news feed highlights company announcements that track the progress of this multi-asset OX2R pipeline and related corporate developments.
Investors and followers of Centessa can use this page to review news about the Phase 2a CRYSTAL‑1 study of ORX750 in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), as well as updates on the Phase 1 program for ORX142 in healthy volunteers and IND-enabling work for ORX489 in neuropsychiatric disorders. The company’s releases also describe preclinical data on additional OX2R agonists, including findings in animal models relevant to neuropsychiatric indications.
Beyond clinical milestones, CNTA news items cover capital markets and corporate events such as public offerings of American Depositary Shares, at-the-market sales agreements, participation in healthcare and investor conferences, and leadership changes reported via press release and Form 8‑K. These disclosures provide context on how Centessa funds and organizes its development activities.
This news page aggregates official communications from Centessa and related SEC-reported events, allowing readers to follow clinical data readouts, regulatory milestones like IND clearance, financing transactions and strategic updates around the company’s orexin-focused franchise. For ongoing research into CNTA, this stream offers a centralized view of the company’s reported progress and key announcements over time.
Centessa Pharmaceuticals (NASDAQ: CNTA) reported a net loss of $60.8 million for Q4 2021 and $381.1 million for the full year, primarily driven by $220 million in R&D expenses from acquisitions. The company holds $595.1 million in cash as of December 31, 2021, aimed to fund operations into early 2024.
The company focuses on rare diseases and immuno-oncology, with SerpinPC registrational studies planned for Hemophilia B in 2H 2022, and Lixivaptan in a Phase 3 trial for ADPKD. Centessa's '4x24' goal aims for four registrational programs by 2024.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced that CEO Saurabh Saha will present at the Guggenheim Genomic Medicines & Rare Disease Day on March 31, 2022, at 11:00 AM ET. Investors can access the live webcast and archived recordings on the company’s investor relations website.
This presentation aligns with Centessa's mission to develop impactful medicines across various therapeutic areas, including oncology, hematology, and neuroscience. For more details, visit Centessa's website.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced the appointment of Antoine Yver, MD, MSc, as Executive Vice President and Chairman of Development, and Javad Shahidi, MD, MSc, as Chief Medical Officer. Dr. Yver will oversee overall development strategy, while Dr. Shahidi will manage clinical development teams. CEO Saurabh Saha emphasized the recruitment of talent amid plans for registrational trials and entry of multiple assets into clinical phases. Dr. Shahidi's previous role at Daiichi Sankyo involved leading significant oncology programs.
Centessa Pharmaceuticals (Nasdaq: CNTA) and its subsidiary Palladio Biosciences have initiated dosing in the pivotal Phase 3 ACTION Study, evaluating lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD). This trial aims to enroll ~1,350 participants across 200 sites in over 20 countries, with completion expected in H2 2023. Positive results may lead to a New Drug Application (NDA) submission post the double-blind study phase. Lixivaptan's unique profile may mitigate liver toxicity issues associated with existing ADPKD therapies, enhancing its therapeutic potential.
Centessa Pharmaceuticals (CNTA) has initiated the global ACTION Study, a pivotal Phase 3 clinical trial investigating lixivaptan as a treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD). With up to 1,350 subjects, the double-blind trial aims to assess lixivaptan's efficacy in slowing renal function decline over 52 weeks. Initial safety data from four subjects in the ALERT Study show successful titration of lixivaptan without liver toxicity, while a new patent protects lixivaptan use in ADPKD until 2038. The first subject is expected to be dosed in Q1 2022.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced its upcoming addition to the NASDAQ Biotechnology Index, effective December 20, 2021. This index includes companies classified as Biotech or Pharma that meet specified criteria. The announcement reflects Centessa's innovative, asset-centric model aimed at developing impactful medicines across multiple therapeutic areas such as oncology and immunology. This addition may enhance Centessa's visibility and investor interest, potentially influencing its stock performance positively.
IMIDomics Inc. has established its Scientific and Business Advisory Boards to enhance its mission in developing precision medicines for immune-mediated inflammatory diseases (IMIDs) such as lupus and rheumatoid arthritis. The boards consist of leading experts including Dan Littman and Luisa Salter-Cid, aiding IMIDomics in leveraging its Precision Discovery Engine, which integrates extensive clinical data to innovate therapies for IMIDs. CEO Juan Harrison emphasizes the importance of advancing treatment options for these complex and often undertreated conditions.
Epizyme, Inc. has announced the appointment of two new members to its Board of Directors: Roy A. Beveridge, M.D., a clinical oncology executive, and Carol Stuckley, M.B.A., a seasoned pharmaceutical and financial leader. Beveridge brings over 30 years of experience in oncology and healthcare policy, while Stuckley offers 25 years of financial expertise from Pfizer. The company also announced the resignation of Andrew R. Allen, M.D., Ph.D., effective November 16, 2021. The leadership changes aim to enhance Epizyme's focus on epigenetic therapies and support its growth trajectory.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced promising topline results from a proof-of-concept study of SerpinPC in severe hemophilia A and B, showing an 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds. The company also provided proof-of-mechanism data for ZF874 in Alpha-1 Antitrypsin Deficiency. A $300 million financing facility was secured with Oberland Capital, strengthening the company's financial position. Centessa incurred a net loss of $40.2 million for Q3 2021, with cash and equivalents at $653.4 million, anticipated to fund operations until mid-2024.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced that CEO Saurabh Saha will present at two upcoming investor conferences. The first is the Jefferies London Healthcare Conference on November 18, 2021, where the presentation will be available on-demand starting at 3:00 AM ET. The second is the Evercore ISI HealthCONx Conference on December 2, 2021, featuring a fireside chat at 4:20 PM ET. Access to live webcasts and archives will be available on the Centessa investor relations website.